6 results on '"Everitt, Aaron A."'
Search Results
2. IFITM3 restricts the morbidity and mortality associated with influenza
- Author
-
Everitt, Aaron R., Clare, Simon, Pertel, Thomas, John, Sinu P., Wash, Rachael S., Smith, Sarah E., Chin, Christopher R., Feeley, Eric M., Sims, Jennifer S., Adams, David J., Wise, Helen M., Kane, Leanne, Goulding, David, Digard, Paul, Anttila, Verneri, Baillie, Kenneth J., Walsh, Tim S., Hume, David A., Palotie, Aarno, Xue, Yali, Colonna, Vincenza, Tyler-Smith, Chris, Dunning, Jake, Gordon, Stephen B., Everingham, K., Dawson, H., Hope, D., Ramsay, P., Walsh (Local Lead Investigator), T. S., Campbell, A., Kerr, S., Harrison, D., Rowan, K., Addison, J., Donald, N., Galt, S., Noble, D., Taylor, J., Webster (Local Lead Investigator), N., Taylor (Local Lead Investigator), I., Aldridge (Local Lead Investigator), J., Dornan, R., Richard, C., Gilmour, D., Simmons (Local Lead Investigator), R., White (Local Lead Investigator), R., Jardine, C., Williams (Local Lead Investigator), D., Booth (Local Lead Investigator), M., Quasim, T., Watson, V., Henry, P., Munro, F., Bell, L., Ruddy (Local Lead Investigator), J., Cole (Local Lead Investigator), S., Southward, J., Allcoat, P., Gray, S., McDougall (Local Lead Investigator), M., Matheson, J., Whiteside (Local Lead Investigator), J., Alcorn, D., Rooney (Local Lead Investigator), K., Sundaram, R., Imrie (Local Lead Investigator), G., Bruce, J., McGuigan, K., Moultrie (Local Lead Investigator), S., Cairns (Local Lead Investigator), C., Grant, J., Hughes, M., Murdoch (Local Lead Investigator), C., Davidson (Local Lead Investigator), A., Harris, G., Paterson, R., Wallis (Local Lead Investigator), C., Binning (Local Lead Investigator), S., Pollock, M., Antonelli, J., Duncan, A., Gibson, J., McCulloch, C., Murphy, L., Haley, C., Faulkner, G., Freeman, T., Hume, D. A., Baillie (Principal Investigator), J. K., Chaussabel, D., Adamson, W. E., Carman, W. F., Thompson, C., Zambon, M. C., Aylin, P., Ashby, D., Barclay, W. S., Brett, S. J., Cookson, W. O., Drumright, L. N., Dunning, J., Elderfield, R. A., Garcia-Alvarez, L., Gazzard, B. G., Griffiths, M. J., Habibi, M. S., Hansel, T. T., Herberg, J. A., Holmes, A. H., Hussell, T., Johnston, S. L., Kon, O. M., Levin, M., Moffatt, M. F., Nadel, S., Openshaw, P. J., Warner, J. O., Aston, S. J., Gordon, S. B., Hay, A., McCauley, J., OʼGarra, A., Banchereau, J., Hayward, A., Baillie, J. K., Simmonds, P., McNamara, P. S., Semple, M. G., Smyth, R. L., Nguyen-Van-Tam, J. S., Ho, L.-P., McMichael, A. J., Kellam, P., Smyth, Rosalind L., Openshaw, Peter J., Dougan, Gordon, Brass, Abraham L., and Kellam, Paul
- Published
- 2012
- Full Text
- View/download PDF
3. Amphotericin B Increases Influenza A Virus Infection by Preventing IFITM3-Mediated Restriction.
- Author
-
Lin, Tsai-Yu, Chin, Christopher R., Everitt, Aaron R., Clare, Simon, Perreira, Jill M., Savidis, George, Aker, Aaron M., John, Sinu P., Sarlah, David, Carreira, Erick M., Elledge, Stephen J., Kellam, Paul, and Brass, Abraham L.
- Abstract
Summary: The IFITMs inhibit influenza A virus (IAV) replication in vitro and in vivo. Here, we establish that the antimycotic heptaen, amphotericin B (AmphoB), prevents IFITM3-mediated restriction of IAV, thereby increasing viral replication. Consistent with its neutralization of IFITM3, a clinical preparation of AmphoB, AmBisome, reduces the majority of interferon’s protective effect against IAV in vitro. Mechanistic studies reveal that IFITM1 decreases host-membrane fluidity, suggesting both a possible mechanism for IFITM-mediated restriction and its negation by AmphoB. Notably, we reveal that mice treated with AmBisome succumbed to a normally mild IAV infection, similar to animals deficient in Ifitm3. Therefore, patients receiving antifungal therapy with clinical preparations of AmphoB may be functionally immunocompromised and thus more vulnerable to influenza, as well as other IFITM3-restricted viral infections. [Copyright &y& Elsevier]
- Published
- 2013
- Full Text
- View/download PDF
4. IFITM3 restricts the morbidity and mortality associated with influenza
- Author
-
Everitt, Aaron R., Clare, Simon, Pertel, Thomas Charles, John, Sinu P., Wash, Rachael S., Smith, Sarah E., Chin, Christopher R., Feeley, Eric M., Sims, Jennifer S., Adams, David J., Wise, Helen M., Kane, Leanne, Goulding, David A., Digard, Paul, Anttila, Verneri, Baillie, J. Kenneth, Walsh, Tim S., Hume, David A., Palotie, Aarno, Xue, Yali, Colonna, Vincenza, Tyler-Smith, Chris, Dunning, Jake, Gordon, Stephen B., Smyth, Rosalind L., Openshaw, Peter, Dougan, Gordon, Brass, Abraham L., and Kellam, Paul
- Published
- 2013
- Full Text
- View/download PDF
5. Defining the Range of Pathogens Susceptible to Ifitm3 Restriction Using a Knockout Mouse Model.
- Author
-
Everitt, Aaron R., Clare, Simon, McDonald, Jacqueline U., Kane, Leanne, Harcourt, Katherine, Ahras, Malika, Lall, Amar, Hale, Christine, Rodgers, Angela, Young, Douglas B., Haque, Ashraful, Billker, Oliver, Tregoning, John S., Dougan, Gordon, and Kellam, Paul
- Subjects
- *
PATHOGENIC microorganisms , *INTERFERONS , *DISEASE susceptibility , *CELLULAR signal transduction , *LABORATORY mice , *SINGLE nucleotide polymorphisms , *INFLUENZA viruses - Abstract
The interferon-inducible transmembrane (IFITM) family of proteins has been shown to restrict a broad range of viruses in vitro and in vivo by halting progress through the late endosomal pathway. Further, single nucleotide polymorphisms (SNPs) in its sequence have been linked with risk of developing severe influenza virus infections in humans. The number of viruses restricted by this host protein has continued to grow since it was first demonstrated as playing an antiviral role; all of which enter cells via the endosomal pathway. We therefore sought to test the limits of antimicrobial restriction by Ifitm3 using a knockout mouse model. We showed that Ifitm3 does not impact on the restriction or pathogenesis of bacterial (Salmonella typhimurium, Citrobacter rodentium, Mycobacterium tuberculosis) or protozoan (Plasmodium berghei) pathogens, despite in vitro evidence. However, Ifitm3 is capable of restricting respiratory syncytial virus (RSV) in vivo either through directly restricting RSV cell infection, or by exerting a previously uncharacterised function controlling disease pathogenesis. This represents the first demonstration of a virus that enters directly through the plasma membrane, without the need for the endosomal pathway, being restricted by the IFITM family; therefore further defining the role of these antiviral proteins. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
6. The CD225 Domain of IFITM3 Is Required for both IFITM Protein Association and Inhibition of Influenza A Virus and engue Virus Replication.
- Author
-
John, Sinu P., Chin, Christopher R., Perreira, Jill M., Feeley, Eric M., Aker, Aaron M., Savidis, George, Smith, Sarah E., Elia, Andrew E. H., Everitt, Aaron R., Vora, Mehul, Pertel, Thomas, Elledge, Stephen J., Kellam, Paul, and Brassa, Abraham L.
- Subjects
- *
INTERFERON inducers , *MEMBRANE proteins , *INFLUENZA A virus , *VIRAL replication , *SINGLE nucleotide polymorphisms , *MOLECULAR dynamics - Abstract
The interferon-induced transmembrane protein 3 (IFITM3) gene is an interferon-stimulated gene that inhibits the replication of multiple pathogenic viruses in vitro and in vivo. IFITM3 is a member of a large protein superfamily, whose members share a functionally undefined area of high amino acid conservation, the CD225 domain. We performed mutational analyses of IFITM3 and identified multiple residues within the CD225 domain, consisting of the first intramembrane domain (intramembrane do-main 1 [IM1]) and a conserved intracellular loop (CIL), that are required for restriction of both influenza A virus (IAV) and den-gue virus (DENV) infection in vitro. Two phenylalanines within IM1 (F75 and F78) also mediate a physical association between IFITM proteins, and the loss of this interaction decreases IFITM3-mediated restriction. By extension, similar IM1-mediated as-sociations may contribute to the functions of additional members of the CD225 domain family. IFITM3's distal N-terminal do-main is also needed for full antiviral activity, including a tyrosine (Y20), whose alteration results in mislocalization of a portion of IFITM3 to the cell periphery and surface. Comparative analyses demonstrate that similar molecular determinants are needed for IFITM3's restriction of both IAV and DENV. However, a portion of the CIL including Y99 and R87 is preferentially needed for inhibition of the orthomyxovirus. Several IFITM3 proteins engineered with rare single-nucleotide polymorphisms demon-strated reduced expression or mislocalization, and these events were associated with enhanced viral replication in vitro, suggest-ing that possessing such alleles may impact an individual's risk for viral infection. On the basis of this and other data, we propose a model for IFITM3-mediated restriction. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.